Analysis of a novel immune checkpoint, Siglec‐15, in pancreatic ductal adenocarcinoma

Siglec‐15, a novel immune checkpoint, is an emerging target for next‐generation cancer immunotherapy. However, the role of Siglec‐15 in pancreatic ductal adenocarcinoma (PDAC) remains poorly understood. We investigated the expression of Siglec‐15 and its association with clinicopathological characte...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xianlong, Mo, Shengwei, Zhang, Yue, Ma, Heng, Lu, Zhaohui, Yu, Shuangni, Chen, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977273/
https://www.ncbi.nlm.nih.gov/pubmed/35083884
http://dx.doi.org/10.1002/cjp2.260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977273/
https://www.ncbi.nlm.nih.gov/pubmed/35083884
http://dx.doi.org/10.1002/cjp2.260

Ejemplares similares